Real World Data
Optimising the use of real world data to drive effective outcomes
Real world evidence (RWE) continues to drive healthcare and research discussions and decisions. ICON delivers Real World Intelligence®, bringing together innovative thinking and technology solutions to identify, generate, and communicate the clinical, safety and cost-effectiveness evidence that regulators, payers and providers demand.
Generate RWE using cross sectional studies and medical chart reviews
Download our white paper, Real World Evidence Generation: The Value of Cross-Sectional Studies and Medical Chart Reviews to learn how this hybrid approach to study design can be advantageous for generating real world evidence. Get insights on the issues you need to consider to ensure that your study is planned to produce robust scientific data that can be extrapolated beyond the study population.
.jpg?crop=yes&w=310&h=310&itok=CymNI0IX "Real world data webinar"){kind=icon}
Real World Data blogs and media contributions
-
Media article: Real world evidence and the patient experience: Involving rare disease patients for successful trials
ICON's William C Maier and Maggie Adamski discuss case studies from their line of work, and how real world evidence can support those suffering with rare diseases around the world.
-
Media article: The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions.
-
Blog: Encouraging patient participation in real world studies
Real world data offers an alternative approach to observational research, particularly to inform decisions on patient needs and preferences.
-
4d78.jpg "Real-world data regulatory applications")
Media article: Ask the Experts: Advancing real-world data in the precision medicine era
A panel discussion providing perspectives on the applications, challenges and future of the collection of biospecimens, and how real-world data can be used to advance the field of precision medicine.
-
Media article: Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance.
-
Blog: Towards a data-driven feasibility assessment
Explore how conducting a thorough data-driven feasibility assessment sets sponsors up for success in the operational aspects of their trials.
-
Blog: The digitization of clinical drug development
ICON expert Dr. Uma Arumugam takes a look at the advancements in digital applications and technology impacting clinical drug development.
-
Blog: Improving access and reimbursement for specialty therapies
Clinical development can better satisfy the evidence needs of payers, and not incorporating the needs of payers early into trial designs risks the need to spend more money later on.
.jpg?crop=yes&w=555&h=292&a=0,24&itok=xT6jOkng "Real-world data regulatory applications"){kind=icon}
Reduce the cost of post-market surveillance with real world data
Real-World Evidence (RWE) is derived from Real World Data (RWD), and early use of Real World Evidence can cut post-marketing study costs and Medical Device time-to-market.
Devices are especially good candidates for early RWE use since evidence collected in the context of actual patient care from previously approved versions or similar devices often can be used to supplement findings from clinical trials of the latest version in development.
RWD and Alzheimer's disease
Real world data such as sleep quality and quantity have clinical relevance in Alzheimer's disease, providing objective measures of sleep and activity patterns that are not subject to patient recall bias. Review the use of wearables in Alzheimer’s disease to provide objective measures of sleep and activity patterns that are not subject to patient recall bias.
Harnessing technology to maximise RWE value
Late phase research is undergoing rapid transformation due to the impact of healthcare digitalisation and the greater availability of and access to Real World Data (RWD).
Meeting evidentiary needs with EHRs
How can the abundance of Real World Data (RWD) from Electronic Health Records (EHRs) enhance your late phase research studies while decreasing study costs?
.jpg?crop=yes&w=232&h=232&itok=ZelPtNTM "Real-world data regulatory applications"){kind=icon}
Receive more insights on Real World Data
Please visit ICON's Preference Centre and select 'Real World Evidence' under 'Topics of Interest' to receive new insights on oncology.